Advisory Council February 2017 Meeting Presentation: NINDS Update



Friday, February 3, 2017

Printer Friendly Version in PDF Format (11 PDF pages)


NINDS Update: National Plan to Address Alzheimer's Disease ADRD Milestones

Roderick A. Corriveau, Ph.D.
Program Director and
AD/ADRD Program Planning Lead, NINDS

NINDS Complements the NIA's Lead Role at the NIH in Responding to the National Plan

  • Alzheimer's Disease-Related Dementias (ADRD)
    • Related dementias include frontotemporal dementia (FTD), Lewy body (LBD), mixed, and vascular dementias (VCID).
  • Goal 1: Prevent and Effectively Treat AD/ADRD by 2025
    • HHS will identify interim milestones and set ambitious deadlines for achieving these milestones in order to meet this goal.
  • Action 1.A.8
    • NINDS/NIH to regularly convene stakeholders for ADRD Summit to review research progress and refine and add new milestones as appropriate, based on recent scientific discoveries.
  • NIA leads overall response to National Plan, as well as the priority setting AD Summits
  • Interest across neurodegenerative disorders: potential for mechanistic, translational, and clinical synergy
  • NINDS AD portfolio focuses on molecular mechanisms of disease pathophysiology: $66.6M in FY15 (NIH $589M)
  • NINDS ADRD portfolio:
    • FTD: $19M in FY15 (NIH $36M)
    • LBD: $7M in FY15 (NIH $15M)
    • VCID: $10M in FY15 (NIH $72M)
  • Lead for NAPA-Responsive ADRD Summits (2013, 2016)

NIH AD/ADRD Research Planning and Relationship to Funding

Flow Chart.

ADRD 2016 Summit

  • David M. Holtzman, MD Washington University SOM, Scientific Chair
  • Roderick A. Corriveau, PhD NINDS, Program Director, NIH Lead
  • Steering Committee
    • Karen Chen, Tom Montine, Bruce Obviagele, Ron Petersen, Tony Phelps
  • Session Committees -- 67 Leading Scientists & NGO members
    • Overarching: MED (Chairs: D. Knopman, D. Bennett); Health Disparities (J. Manly); NGO* (*new in 2016; S. Dickinson, H. Fillit; A. Taylor [nomenclature])
    • Disease-Specific: LBD (K. Marder, D. Dickson); FTD (W. Seeley, M. Hutton); VCID (S. Greenberg, T. Carmichael)


  • Steering committee formed September 2015
  • Pre-conference work from October 2015 to March 2016
  • Alzheimer's Disease-Related Dementias Summit 2016
    • Presented rationale for revisions to 2013 milestones
    • Lively discussion among experts
    • Feedback/opinions from audience; wide range of stakeholders
      • 490 registrants, 325 in person, 300 online
    • Closed session to plan post-conference work
  • Post-conference work from April to August 2016
  • Report presented to NINDS Council & approved, 9/2016
  • Report & 37 milestones delivered to NAPA Council, 11/2017
  • Publication under preparation


  • Many more recommendations/milestones were suggested than made the final list
    • Broad agreement that all items included are important research goals
  • Prioritization with Timelines
    • Based on advancing scientific discovery needed to achieve the NAPA goal of prevention or effective intervention for ADRD by 2025
    • Each Topic Committee reached consensus on priority after long deliberation
  • Timelines are independent of priority
  • Aspirational, Operational: both are needed

AD/ADRD Research Increases at NIH

Bar Chart: FY2011 ($448M); FY2012 ($503M); FY2013 ($504M); FY2014 ($562M); FY2015 ($631M); FY2016 ($991M projected); FY2017 ($991M projected).

NIH Investment in ADRD Research (millions)

Fiscal Year: 2012 2013 2014 2015
Frontotemporal Dementia $26 $32 $37 $36
Lewy Body Dementia Not Determined Not Determined $15 $15
VCID Not Determined Not Determined $45 $72
ADRD Total* Not Determined Not Determined Not Determined $120
* (unofficial 2016 Est: $161)

What Does this Mean for the NIH and NINDS in Moving Forward National Plan Goals?

  1. Funds have been added for AD/ADRD research. For example, NIH, via NIA, during FY16 received a $360 M increase in annual funding. During FY16 ADRD research had an estimated $41 M increase in funding.
  2. NIA and NINDS, as the leading NIH institutes in supporting AD/ADRD research, are working together to oversee expenditure of these additional funds.
  3. Added funds shared by NIA with NINDS are used in 2 major ways:
    • Funding announcements for ADRD research, for example via the NINDS RFAs this Council round
    • Investigator-initiated AD/ADRD research beyond the payline

FY16 NINDS ADRD Initiatives Responsive to National Plan

  • RFA-NS16-022: Biomarkers for the Lewy Body Dementias (U01)
    • Milestones: LBD FA1-R2, FA2-R3, FA2-R4, FA3-R5, FA3-R6; 4 awards
  • RFA-NS16-023: Center without Walls for the Identification & Validation of Molecular Mechanisms Contributing to Tau Pathogenesis & Associated Neurodegeneration in Frontotemporal Degeneration (U54)
    • Milestone: FTD FA1-R1; 2 awards
  • RFA-NS16-021: Mechanistic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment & Dementia (VCID)(R01)
    • Milestone: VCID FA1-R2; 3 awards
  • RFA-NS16-019, -020: Small Vessel Vascular Contributions to Cognitive Impairment & Dementia (VCID) Biomarkers Consortium: Coordinating Center (U24) and Biomarkers Development Projects (UH2/UH3)
    • Milestone: VCID FA2-R1; 8 awards
    • MarkVCID Consortium Established

MarkVCID: National Consortium Moving VCID Biomarkers Toward the Clinic

  • Why was MarkVCID established? To meet large unmet need for clinical trial-ready VCID biomarkers with high potential for positive impact in public health.
  • Established via RFA-16-020, RFA-16-021
    • 7 project sites across the Unites States: CA, IL, KY, MD, MA, NM
    • Coordinating Center PI: Dr. Steve Greenberg, MGH
  • External Advisory Committee: Billy Dunn, Ron Petersen, Tom Montine, Geert Jan Biessels, Rebecca Gottesman
  • Consortium Kickoff Meeting in February 2017

The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID)

Overlapping diagram showing the intersection of Stroke and Alzheimer's.
Corriveau, Koroshetz et al., Cell Mol Neurobiol (2016) 36:281-288
Synder, Corriveau et al., Alzheimer's & Dementia (2014) 1-8

ADRD Initiatives that Address Mixed Etiologies

Overlapping diagram showing the intersection of Frontotemporal dementias, Alzheimer's disease, Vascular contributions and Lewy body dementias.
  • PAR-17-028: Common Mechanisms and Interactions Among Neurodegenerative Diseases (R01)
    • Milestone: MED FA1-R2, MED FA2-R5
  • RFA-AG-15-010: Interdisciplinary Research to Understand the Vascular Contributions to Alzheimer's Disease (M2OVE AD Consortium)
    • Milestone: VCID FA2-R2

FY17 NINDS ADRD Initiatives Responsive to National Plan

  • RFA-NS17-016: Leveraging Existing Resources for Research on Lewy Body Dementia (R03)
    • Milestone: LBD FA3-R5, FA3-R6
  • RFA-NS17-017: Frontotemporal Degeneration (FTD) Sequencing Consortium: Discovery, Replication and Validation (UG3/UH3)
    • Milestone: FTD FA2-R1

FY17 NINDS ADRD Concepts Responsive to National Plan

  • Detecting Cognitive Impairment, Including Dementia, in Primary Care and Other Everyday Clinical Settings for the General Public and in Health Disparities Populations
    • Milestone: MED FA1-R1

Health Disparities NIA ADRD Initiative NINDS has Joined

  • PAR-15-349: Health Disparities & AD (R01)
  • Milestone: FA1-R1

NGO Session: Catalyzing Research Through Unique Programs & Partnerships

  • Milestone 1. Establish more effective communication between NIH and the NGOs on activities and progress toward the ADRD goals in the off-years between the triennial ADRD Research Summits
    • Post all ADRD Summit 2016 milestones and success criteria publicly [complete]
    • NINDS to present annually to NAPA Council on progress toward the ADRD goals/milestones from 2017 onwards [on-going]
    • Convene annual meetings during which NINDS, NIA, and NGOs share activities, funding-related information, and progress relevant to the ADRD recommendations [on-going]

Special Joint Session

  • Milestone: Develop Consistent Nomenclature in Dementia Research & Care
    • Organize a working group of dementia stakeholders, including founding partnerships with health disparities communities, to review the current nomenclature used in public awareness, clinical care services and research and to propose strategies to help advance early differential diagnosis and the understanding of dementia and its underlying causes

NAPA Council's 2016 Recommendation #4:

  • Emphasis should be given to the standardization of terminology in dealing with cognitive and dementing disorders.
    1. An integrated conference should be convened to develop consistent language for cognitive disorders among the scientists, care providers and the public.
    2. Engage all of the stakeholders around these issues to reach a consensus for the benefit of persons with dementia, their family members and caregivers, and the scientific and service communities.

Upcoming Summits

  • Dementia Care and Services Research Summit
    • October 16-17, 2017
  • The 3rd Alzheimer's Disease (AD) Summit
    • March 2018
  • The 3rd Alzheimer's Disease-Related Dementias (ADRD) Summit
    • March 2019

NIH Mind Your Risks

NIH Mind Your Risks screen shot.

Thank You NIH Leadership & Colleagues

  • Walter Koroshetz
  • Richard Hodes
  • Robert Finkelstein
  • David Owens
  • Marian Emr
  • Paul Scott
  • Ernie Lyons
  • Tony Phelps
  • Amelie Gubitz
  • Beth-Anne Sieber
  • Birgit Neuhuber
  • Carole Jelsema
  • Christine Swanson
  • Christine Torborg
  • Claudia Moy
  • Debra Babcock
  • Joel Saydoff
  • Jordan Gladman
  • Linda MacArthur
  • Linda McGavern
  • Marg Sutherland
  • Monica Flemming
  • Natalia Strunnikova
  • Nena Wells
  • Nina Silverberg
  • Salina Waddy
  • Patricia Walicke
  • Sophia Jeon
  • Susan Fowler
  • Tracey David
  • Jonathan Sabbagh

Thank you to our ADRD Summit 2016 partners:

  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging
  • NIH Office of Disease Prevention
  • Foundation for the National Institutes of Health
  • Alzheimer's Association
  • Accelerate Cure/Treatments for Alzheimer's Disease
  • American Heart Association
  • Association for Frontotemporal Degeneration
  • Axovant Dementia Solutions
  • BrightFocus Foundation
  • Leaders Engaged on Alzheimer's Disease

Return to

National Alzheimer's Project Act Home Page

Advisory Council on Alzheimer's Research, Care, and Services Page

Advisory Council on Alzheimer's Research, Care, and Services Meetings Page